Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2015, Article ID 132030, 6 pages
http://dx.doi.org/10.1155/2015/132030
Case Report

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

1Department of Gastroenterology, Otaru General Hospital, 1-2-1 Wakamatu, Otaru 047-8550, Japan
2Department of Surgery, Otaru General Hospital, 1-2-1 Wakamatu, Otaru 047-8550, Japan
3Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan
4Department of Laboratory Medicine, Otaru General Hospital, 1-2-1 Wakamatu, Otaru 047-8550, Japan

Received 22 October 2014; Accepted 10 March 2015

Academic Editor: Olga I. Giouleme

Copyright © 2015 Yu Ishimine et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. A 74-year-old woman received trastuzumab-containing chemotherapy for HER2-positive MUGC. She had a marked response to 8 months of chemotherapy, and gastrectomy and hepatic metastasectomy with curative intent were performed. The resected specimen showed complete loss of HER2 positivity in the residual tumor. For MUGC, a change in HER2 status during the course of the disease with or without chemotherapy has rarely been reported. However, in breast cancer, a significant frequency of change in HER2 status during the course of disease has been reported, and reevaluation of HER2 positivity in metastatic/recurrent sites is recommended. The choice of trastuzumab for MUGC is currently based on the HER2 status of the primary tumor at the time of initial diagnosis, without reassessment of HER2 status during the course of disease and/or in metastatic/recurrent sites, on the assumption that HER2 status is stable. However, our case casts doubt on the stability of HER2 in gastric cancer.